Hemopexin Antibody (698813) [Alexa Fluor® 647]

• Applications: WB, IHC
• Clone: 698813
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 647

Hemopexin Antibody (698813) [Alexa Fluor® 647] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Hemopexin
  Thr24-His462
  Accession # P02790
• Specificity: Detects human Hemopexin in direct ELISAs and Western blots. In Western blots, approximately 5-10% cross-reactivity with recombinant human MMP-1, -3, -10, -12, and -13 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from ascites

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Hemopexin Antibody (698813) [Alexa Fluor® 647]

• Beta-1B-glycoprotein
• FLJ56652
• Hemopexin
• HPX
• HX

Background

Hemopexin (HPX) is a 60 kDa plasma glycoprotein with two four-bladed beta -propeller folds. This structural motif has been found in other proteins including collagenases and provides sites for protein-protein interactions (1-3). The liver is the major synthesizing organ. Expression in the central nervous system, in the retina, and in peripheral nerves has also been observed. Hemopexin belongs to the family of the acute-phase proteins whose synthesis is induced after an inflammatory event. Hemopexin participates in maintaining and recycling the iron pool by utilizing its high binding affinity toward heme composed of protoporphyrin IX and iron. It also functions in preventing oxidation caused by heme after hemolysis. Hydrophobic heme molecules can intercalate into lipid membranes and participate in the oxidation of lipid membrane components through the Fenton reaction resulting in lipid peroxidation. Hemopexin undergoes a conformational change upon the binding of heme. The conformational change allows hemopexin to interact with a specific receptor, forming a complex which is then internalized. In the plasma, it is likely that heme binds albumin (35-55 g/L) first because of the higher concentration of albumin in plasma than hemopexin (0.5-1.2 g/L), and is then transferred to hemopexin, which has a much higher affinity (K_d ~ 1 pM) toward heme. Heme concentrations in plasma increase after hemolysis, which is associated with several pathological conditions such as reperfusion injury and ischemia.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P02790(Human)